De Luna-Sánchez MP, Soriano-Rosas J, Mora-Mendoza I

Language: Spanish
References: 11
Page: 11-16
PDF size: 226.12 Kb.

ABSTRACT

Introduction: Malignant mesenchymal neoplasms tumors with great local and metastatic destructive effects. Immunohistochemistry (IHC) antibodies of recent appearance are currently available that can support the diagnosis of certainty. Objective: To evaluate the usefulness of IHC as an auxiliary tool for the diagnosis of certainty of these neoplasms; determining its prevalence and age distribution in our population. Material and methods: Observational, ambispective, cross-sectional and descriptive study, collected the histopathological diagnoses of malignant mesenchymal malignancies of soft tissues emitted in the Department of Pathological Anatomy from January 2012 to June 2017. IHC antibodies were performed (MDM-2, CDK-4, TLE-1, MUC-4 and SOX-10) in different sarcomas to determine its diagnostic utility. Results: 110 cases were collected, in 54 evaluated with MDM-2 and CDK-4 greater specificity was observed in liposarcomas, nine synovial sarcomas with TLE-1 with positivity of 100% in all cases, four malignant tumors of nerve sheath with SOX-10 and S-100 confirming utility in the diagnosis. Conclusions: IHC is a useful tool for the diagnosis of malignant mesenchymal neoplasms, since it gives lines of differentiation in specific tumors that help to guide the pathologist towards a diagnosis of certainty.

REFERENCES

1. Banerjee R, Bandopadhyay D, Abilash VG. Epidemiology, pathology, types and diagnosis of soft tissue sarcoma: a research review. Asian J Pharm Clin Res. 2013; 6 Suppl 3: 18-25.

2. Burningham Z, Hashibe M, Spector L et al. The epidemiology of sarcoma. Clinical Sarcoma Research. 2012; 2: 14.

3. Kotilingam D, Lev DC, Lazar AJ, Pollock RE. Staging soft tissue sarcoma: evolution and change. CA Cancer J Clin. 2006; 56: 282-291.

4. Ariyan CE, Brady MS. History of regional chemotherapy for cancer of the extremities. Int J Hyperthermia. 2008; 24 (3): 185-192.

5. Rizo-Ríos P, Sierra-Colindres MI, Vázquez-Piñón G, Cano-Guadiana M, Meneses-García A, Mohar A. Registro hospitalario de cáncer: compendio de cáncer 2000-2004. México: Instituto Nacional de Cancerología; 2007. PP. 203-287.

6. García Del Muro X et al. Guía de práctica clínica en los sarcomas de partes blandas. Med Clin (Barc). 2011; 136 (9): 408.e1-408.e18.

7. Lurkin A, Ducimetière F, Vince DR, Decouvelaere AV, Cellier D, Gilly FN et al. Epidemiological evaluation of concordance between initial diagnosis and central pathology review in a comprehensive and prospective series of sarcoma patients in the Rhone-Alpes region. BMC Cancer. 2010; 10: 150.

8. Valkov A, Sorbye SW, Kilvaer TK, Donnem T, Smeland E et al. The prognostic impact of TGF-b1, fascin, NF-kB and PKC-f expression in soft tissue sarcomas. PLoS ONE. 2011; 6 (3): e17507. doi: 10.1371/journal.pone.0017507.

9. Ducimetière F, Lurkin A, Ranchère-Vince D, Decouvelaere AV, Péoc’h M, Istier L et al. Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing. PLoS One. 2011; 6 (8): e20294.

10. Moore K. The developing human. Clinically oriented embryology. 8th ed. Saunders; 2008.

11. Fletcher CD, Unni KK, Mertens F eds. Pathology and genetics of tumours of soft tissue and bone. World Health Organization Classification of Tumours. Vol 5. Lyon, France: IARC Press; 2002. p. 120.